I have no problem with analysts underestimating PNV for now. I...

I have no problem with analysts underestimating PNV for now. I am still building my holding as the price fluctuates.and taking opportunities created by underestimating the company. Today was a great opportunity.

Focusing on lack of profitability where the company is establishing markets globally with very strong sales increases every single quarter is, to put it mildly short-sighted and simple-minded.
If the costs did not increase with sales increase, I would be pretty amazed and asking the auditors to have another look. The cost increase rate is LESS than the sales increase rate so I have zero concerns. .

Also - no debt as interest rates rise and weak AUD with biggest market in USD. Most ordinary AU expenses are being paid by US income because that market is already very profitable. We raised CAP to accelerate ROW growth and boost manufacturing in Aus.

The workforce they have brought on in US are specialists in selling to surgeons and many have moved over from the competitor. Pretty experienced I would say.
In ROW there will be a variety of experience but in most developed countries there will be no shortage of clinical sales staff that get the benefit of the product IMO. In places such as India, there hasn't been an option for them in the price range BTM can provide so there will be a learning curve but they will be keen and the market need will be great.